IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Atty Dkt. 1579-601
C# M#



HAYNES, Barton F. Group Art Unit: 1644

Serial No. 09/956,940 Examiner: Schwadron, R.

Filed: Septemb r 21, 200 Date: December 12, 2003

Title: USE OF SYNTHETIC PEPTIDES TO INDUCE TOLERANCE TO PATHOGENIC T AND B CELL EPITOPES OF AUTOANTIGENS OR INFECTIOUS AGENTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.**

F s are attached as calculated below:

Total effective claims after amendment **0** minus highest number previously paid for **20** (at least 20) = 0 x $ 18.00	$	0.00
Independent claims after amendment **0** minus highest number previously paid for **3** (at least 3) = 0 x $ 86.00	$	0.00
If proper multiple dependent claims now added for first time, add $290.00 (ignore improper)	$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) ($110.00/1 month; $420.00/2 months; $950.00/3 months)	$	0.00
Terminal disclaimer enclosed, add $ 110.00	$	0.00
☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) ($770.00) ☐ Please enter the previously unentered , filed ☐ Submission attached	$	0.00
Subtotal	$	**0.00**
If "small entity," then enter half (1/2) of subtotal and subtract ☐ Applicant claims "small entity" status. ☐ Statement filed herewith	-$	0.00
Rule 56 Information Disclosure Statement Filing Fee ($180.00)	$	180.00
Assignment Recording Fee ($40.00)	$	0.00
Other:		**0.00**
TOTAL FEE TO BE DEBITED	$	**180.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of — Confirmation No. 4369

HAYNES, Barton F. — Atty. Ref.: 1579-601

Serial No. 09/956,940 — Group: 1644

Filed: September 21, 2001 — Examiner: Schwadron, R.

For: USE OF SYNTHETIC PEPTIDES TO INDUCE TOLERANCE TO PATHOGENIC T AND B CELL EPITOPES OF AUTOANTIGENS OR INFECTIOUS AGENTS

* * * * * * * * * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 12, 2003

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C

☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C

☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] *$180.00*

☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]
$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

☒ 4. A list of documents on Form PTO-1449 together with copies* of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

☐ a) The required Statement made in item 8 below; **or**

☒ b) The $180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

☐ a) The fee ($180.00) required by 37 CFR §1.17(p) is submitted herewith; and

☐ b) The required Statement is stated in item 8 below.

☐ 8. Statement under 37 CFR 1.97(e)

☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

* Except for Hu et al (Nature 1986), Fox and Butini et al – as noted on the PTO-1449 Form (page 3), copies can be found in the identified application.

☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____
Mary J. Wilson
Reg. No. 32,955

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1579-601	09/956,940
APPLICANT	
HAYNES, Barton F.	
FILING DATE	**GROUP**
September 21, 2001	1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,812,556	3/1989	Vahlne et al			
		4,659,678	4/1987	Forrest et al			
		4,520,113	5/1985	Gallo et al			
		4,956,273	9/1990	Kennedy et al			
		4,725,669	2/1988	Essex et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
		0 255 190	2/1988	EPO				
		WO 87/02775	5/1987	WIPO				
		WO 91/04051	4/1991	WIPO				
		WO 88/05783	8/1988	WIPO				
		0 273 716	7/1988	EPO				
		WO 91/04273	4/1991	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

		Hart et al, "Synthetic Peptides Containing T and B Cell Epitopes from Human Immunodeficiency Virus Envelope gp120 Induce Anti-HIV Proliferative Responses and High Titers of Neutralizing Antibodies in Rhesus Monkeys", The Journal of Immunology 145(8): 2677-2685 (1990)
		Hart et al, "HIV Synthetic Peptides Containing T and B Cell Epitopes Induce HIV-Specific CD8+ Cytotoxic T Cell Response In Vivo", 1991 FASEB Abstract
		LaRosa et al, "Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing Determinant", Science 249:932-935 (1990)
		Pert et al, "Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity", PNAS USA 83:9254-9258 (1986)
		Sarin et al, "Neutralization of HTLV-III/LAV Replication by Antiserum to Thymosin α_1", Science 232:1135-1138 (1986)
		Kennedy et al, "Antiserum to a Synthetic Peptide Recognizes the HTLV-III Envelope Glycoprotein", Science 231:1556-1559 (1986)
		Chanh et al, "Induction of anti-HIV neutralizing antibodies by synthetic peptides", The EMBO Journal 5(11):3065-3071 (1986)
		Putney et al, "HTLV-III/LAV-Neutralizing Antibodies to an *E. coli*-Produced Fragment of the Virus Envelope", Science 234:1392-1395 (1986)
		Kennedy et al, "Use of a Resin-bound Synthetic Peptide for Identifying a Neutralizing Antigenic Determinant Associated with the Human Immunodeficiency Virus Envelope", J. Biol.I Chem. 262(12):5769-5774 (1987)
		Cease et al, "Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide", Proc. Natl. Acad. Sci. USA 84:4249-4253 (1987)
		Ho et al, "Human Immunodeficiency Virus Neutralizing Antibodies Recognize Several Conserved Domains on the Envelope Glycoproteins", Journal of Virology 61(6):2024-2028 (1987)

*Examiner | Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1579-601	09/956,940
APPLICANT	
HAYNES, Barton F.	
FILING DATE	GROUP
September 21, 2001	1644

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

*EXAMINER INITIAL			
			Krohn et al, "Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men", Proc. Natl. Acad. Sci. USA 84:4994-4998 (1987)
			Starcich et al, "Identification and Characterization of Conserved and Variable Regions in the Envelope Gene of HTLV-III/LAV, the Retrovirus of AIDS", Cell 45:637-648 (1986)
			Robey et al, "Prospect for prevention of human immunodeficiency virus infection: Purified 120-kDa envelope glycoprotein induces neutralizing antibody", Proc. Natl. Acad. Sci. USA 83:7023-7027 (1986)
			Wang et al, "Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein", Proc. Natl. Acad. Sci. USA 83:6159-6163 (1986)
			Sodroski et al, "Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity", Nature 322:470-474 (1986)
			Dalgleish et al, "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus", Nature 312:763-767 (1984)
			Javaherian et al, "Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein", Proc. Natl. Acad. Sci. USA 86:6768-6772 (1989)
			Chakrabarti et al, "Expression of the HTLV-III envelope gene by a recombinant vaccinia virus", Nature 320:535-540 (1986)
			Zarling et al, "Proliferative and Cytotoxic T Cells to AIDS Virus Glycoproteins in Chimpanzees Immunized with a Recombinant Vaccinia Virus Expressing AIDS Virus Envelope Glycoproteins", The Journal of Immunology 139(4):988-990 (1987)
			Hu et al, "Effect of immunization with a vaccinia-HIV *env* recombinant on HIV infection of chimpanzees", Nature 328:721-723 (1987)
			Ratner et al, "Complete nucleotide sequence of the AIDS virus, HTLV-III", Nature 313:277-284 (1985)
			Palker et al, "A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope", Proc. Natl. Acad. Sci. USA 84:2479-2483 (1987)
			Newmark, "Problems with AIDS vaccines", Nature 324:304-305 (1986)
			Norman, "AIDS Virus Presents Moving Target", Science 230:1357-1358 (1985)
			Takahashi et al, "Structural Requirements for Class I MHC Molecule-Mediated Antigen Presentation and Cytotoxic T Cell Recognition of an Immunodominant Determinant of the Human Immunodeficiency Virus Envelope Protein", The Journal of Experimental Medicine 170:2023-2035 (1989)
			Palker et al, "Polyvalent Human Immunodeficiency Virus Synthetic Immunogen Comprised of Envelope gp120 T Helper Cell Sites and B Cell Neutralization Epitopes", The Journal of Immunology 142(10):3612-3619 (1989)
			Girard et al, "Immune Response of Chimpanzees to Active Immunization Against HIV-1", J. of Cell. Biochemistry, UCLA Symp. on Mol. and Cell Biol., page 150 (1990) – Abstract No. L415
			Weinhold et al, "Cell-Mediated Cytolytic Reactivities Against Epitopes Contained Within the V3 Region of HIV-1 GP120", J. of Cell. Biochemistry, UCLA Symp. on Mol. and Cell Biol., page 180 (1990) – Abstract No. L550
			Hart et al, "Neutralizing Anti-HIV Antibodies are Induced in Rhesus Monkeys Immunized with Hybrid Synthetic Peptides (TI-SP10) Containing T and B Cell Epitopes from HIV gp120", J. of Cell. Biochemistry, UCLA Symp. on Mol. and Cell Biol., page 134 (1990) – Abstract No. L315
			Palker et al, "Type-specific neutralization of the human immunodeficiency virus with antibodies to *env*-encoded synthetic peptides", Proc. Natl. Acad. Sci. USA 85:1932-1936 (1988)
			Gallaher, "Detection of a Fusion Peptide Sequence in the Transmembrane Protein of Human Immunodeficiency Virus", Cell 50:327-328 (1987)

*Examiner		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1579-601	09/956,940
APPLICANT	
HAYNES, Barton F.	
FILING DATE	GROUP
September 21, 2001	1644

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

*EXAMINER INITIAL			
			Hu et al, "Expression of AIDS virus envelope gene in recombinant vaccinia viruses", Nature 320(6062):537-540 (1986) – cited in parentmost Application No. 07/093,854 – Abstract attached hereto
			Fox, "No Winners Against AIDS", Biotechnology 12:128 (1994) – cited by Examiner in Application No. 08/546,515
			Butini et al, "Comparative Analysis ...", J. Cell Biochem. Suppl. 18B, J306 (1994) – cited by Examiner in Application No. 08/546,515
			Weinberg et al, "Identification of a Synthetic Peptide That Mimics an HIV Glycoprotein 120 Envelope Conformational Determinant Exposed following Ligation of Glycoprotein 120 by CD4", AIDS Research and Human Retroviruses 13(8):657-664 (1997)
			Haynes et al, "Induction of Neutralizing Anti-HIV Antibodies in Goats and Rhesus Monkeys with Hybrid Synthetic Peptides (T1-SP10) from HIV gp120 that Contain Epitopes Recognized by Both T and B Cells", AIDS Res. and Human Retroviruses 6:38-39 (1990)
			Haynes et al, "Conversion of an Immunogenic Human Immunodeficiency Virus (HIV) Envelope Synthetic Peptide to a Tolerogen in Chimpanzees by the Fusogenic Domain of HIV gp41 Envelope Protein", The Journal of Experimental Medicine 177:717-727 (1993)
			Nossal, "Immunologic Tolerance", Second Edition, edited by William E. Paul, Raven Press Ltd., New York, Fundamental Immunology 19:571-585 (1989)
			Davis et al, "Soluble, Nonantigenic Polyethylene Glycol-Bound Enzymes", Biomedical Polymers Polymeric Materials and Pharmaceuticals for Biomedical Use, pgs. 441-452 (1980)
			Jacobson et al, "Induction of CD4*, Human T Lymphotropic Virus Type-1-Specific Cytotoxic T Lymphocytes from Patients With Ham/TSP", The Journal of Immunology 146(4):1155-1162 (1991)
			Hoffman et al, "An idiotypic network model of AIDS immunopathogenesis", Proc. Natl. Acad. Sci. USA 88:3060-3064 (1991)
			Wigzell, "Prospects for an HIV-vaccine", FASEB J. 5:2406-2411 (1991)
			Papadouli et al, "Antigenic role of single residues within the main immunogenic region of the nicotinic acetylcholine receptor", Biochem. J. 269:239-245 (1990)
			Mori et al, "A Synthetic Oligopeptide Derived from Human Thyrotropin Receptor Sequence Binds to Graves' Immunoglobulin and Inhibits Thyroid Stimulating Antibody Activity but Lacks Interactions with TSH", Biochemical and Biophysical Research Communications 178(1):165-172 (1991)
			Murakami and Mori, "Identification of Immunogenic Regions in Human Thyrotropin Receptor for Immunoglobulin G of Patients with Graves' Disease", Biochemical and Biophysical Research Communications 171(1):512-518 (1990)
			Offner et al, "Encephalitogenic T Cell Clones with Variant Receptor Specificity", The Journal of Immunology 141(11):3828-3832 (1988)
			Wucherpfennig et al, "T-cell recognition of myelin basic protein", Immunology Today 12(8):277-282 (1991)
			Sanui et al, "Identification of An Immunodominant and Highly Immunopathogenic Determinant in the Retinal Interphotoreceptor Retinoid-Binding Protein (IRBP)", The Journal of Experimental Medicine 169:1947-1960 (1989)
			Grassi et al, "Human Immunodeficiency Virus Type 1 gp120 Mimics a Hidden Monomorphic Epitope Borne by Class I Major Histocompatibility Complex Heavy Chains", J. Exp. Med. 174:53-62 (1991)
			Young, "HIV and HLA similarity", Nature 333:215 (1988)
			Golding et al, "Identification of Homologous Regions in Human Immunodeficiency Virus I gp41 and Human MHC Class II β 1 Domain", Journal of Experimental Medicine 167:914-923 (1988)

*Examiner		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1579-601	09/956,940
APPLICANT	
HAYNES, Barton F.	
FILING DATE	GROUP
September 21, 2001	1644

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

*EXAMINER INITIAL			
			Takai et al, "Prokaryotic Expression of the Thyrotropin Receptor and Identification of an Immunogenic Region of the Protein Using Synthetic Peptides", Biochemical and Biophysical Research Communications 179(1):319-326 (1991)
			Piraphatdist et al, "Possible Binding Site of Thyrotropin Binding Inhibitor Immunoglobulin (TBII) on the Thyrotropin (TSH) Receptor, Which is Different from TSH Binding Site", Biochemical and Biophysical Research Communications 172(2):529-536 (1990)
			Hendricks et al, "Alterations in the Antigenic Structure of Two Major HSV-1 Glycoproteins, gC and gB, Influence Immune Regulation and Susceptibility to Murine Herpes Keratitis", The Journal of Immunology 142(1):0263-0269 (1989)
			Weigle, "The Role of the Physical State of Human Gamma Globulin in the In Vivo and In Vitro Induction of Immunological Tolerance", eds. Sercarz and Berzofsky, CRC Press, Inc. Boca Raton, Florida, Immunogenicity of Protein Antigens: Repertoire and Regulation Vol. II, Chapter 5G, pgs. 51-57
			Gahring and Weigle, "The Regulatory Effects of Cytokines on the Induction of a Peripheral Immunologic Tolerance in Mice", The Journal of Immunology 145(5):1318-1323 (1990)
			Milich et al, "Distinction Between Immunogenicity and Tolerogenicity Among HbcAg T Cell Determinants", The Journal of Immunology 143(10):3148-3156 (1989)
			Sprent et al, "T Cell Reactivity to MHC Molecules: Immunity Versus Tolerance", Science 248:1357-1363 (1990)
			Lee and Sehon, "Suppression of Reaginic Antibodies with Modified Allergens", Int. Archs Allergy Appl. Immun. 56:159-170 (1978)
			Lee and Sehon, "Suppression of Reaginic Antibodies with Modified Allergens", Int. Archs Allergy Appl. Immun. 56:193-206 (1978)
			Wie et al, Suppression of Reaginic Antibodies with Modified Allergens", Int. Archs Allergy Appl. Immun. 64:84-99 (1981)
			Lee et al, Suppression of Reaginic Antibodies with Modified Allergens", Int. Archs Allergy Appl. Immun. 64:100-114 (1981)
			Abuchowski et al, "Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol", The Journal of Biological Chemistry 252(11):3578-3581 (1977)
			Abuchowski et al, "Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase", The Journal of Biological Chemistry 252(11):3582-3586 (1977)
			Abuchowski et al, "Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates", Cancer Biochem. Biophys. 7:175-186 (1984)
			Williams, "T Cell Inactivation Linked to Ras Block", Science 271:1234 (1996)
			Lin et al, "Inhibition of Nuclear Translocation of Transcription Factor NF-KB by a synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence", The American Society for Biochemistry and Molecular Biology, Inc. 270(24):14255-14258 (1995)
			Edgington, "How Sweet It is: Selectin-Mediating Drugs", Bio/Technology 10:383-389 (1992)
			Fahey and Schooley, "Status of immune-based therapies in HIV infection and AIDS", Clin. exp. Immunoo. 88:1-5 (1992)
			Woodrow et al, "p21^{ras} Function Is Important for T Cell Antigen Receptor and Protein Kinase C Regulation of Nuclear Factor of Activated T Cells", The Journal of Immunology 150(9):3853-3861 (1993)
			Björling et al, "Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 ca mediate neutralization and antibody-dependent cytotoxic activity", Proc. Natl. Acad. Sci. USA 88:6082-6086 (1991)

*Examiner		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1579-601	09/956,940
APPLICANT	
HAYNES, Barton F.	
FILING DATE	GROUP
September 21, 2001	1644

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

*EXAMINER INITIAL			
			Sanchez-Pescador et al, "Nucleotide Sequence and Expression of an AIDS-Associated Retrovirus (ARV-2)", Science 227:484-492 (1985)
			Berzofsky, "Progress toward Artificial Vaccines for HIV", Vaccines 92:41-50 (1992)
			Haynes et al, "Use of Synthetic Peptides in Primates to Induce High-Titered Neutralizing Antibodies and MHC Class I-Restricted Cytotoxic T Cells Against AIDS Retroviruses: An HLA-Based Vaccine Strategy", 1993 Clinical Research Abstract Form
			Leclerc et al, "A synthetic vaccine constructed by copolymerization of B and T cell determinants", Eur. J. Immunol. 17:269-273 (1987)
			Celada and Sercarz, "Preferential pairing of T-B specificities in the same antigen: the concept of directional help", Vaccine 6:94-98 (1988)
			Milich et al, "Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope", Proc. Natl. Acad. Sci. USA 85:1610-1614 (1988)
			Tam and Lu, "Vaccine engineering: Enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes", Proc. Natl. Acad. Sci. USA 86:9084-9088 (1989)
			Golvano et al, "Polarity of immunogens: implications for vaccine design", Eur. J. Immunol. 20:2363-2366 (1990)
			Aichele et al, "Antiviral Cytotoxic T Cell Response Induced by In Vivo Priming with a Free Synthetic Peptide", J. Exp. Med. 17:1815-1820 (1990)
			Palker et al, "Multivalent Synthetic Peptide Inoculum Induces Neutralizing Antibodies to Divergent HIV Isolates and Anamnestic T-Cell Responses to HIV" In: Early Human Retroviruses, UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 119, Editors, J.E. Groopman et al, Alan R. Liss, Inc., New York, NY (1989)
			Palker et al, "Mapping of Immunogenic and Immunodominant Epitopes of Human Immunodeficiency Virus gp120 with Env-Encoded Synthetic Peptides", Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy, pgs. 161-174 (1988)
			Haynes, "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development", Science 260:1279-1286 (1993)
			Berman et al, "Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160", Nature 345:622-625 (1990)
			Girard et al, "Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus", Proc. Natl. Acad. Sci. USA 88:542-546 (1991)
			Cleghorn et al, "Preparations for HIV-1 Vaccine Efficacy Trials in Trinidad", Prevention and Treatment of AIDS, pg. 156, Abstract J 404
			di Marzo Veronese et al, "Epitope Mimicry by Display of Foreign Peptides on the Surface of Filamentous Bacteriophage", Prevention and Treatment of AIDS, pg. 156, Abstract J 405
			Edghill-Smith et al, "A Unique Subunit Vaccine that Induces Systemic and Mucosal, Cell-Mediated and Humoral Responses Following Oral Administration", Prevention and Treatment of AIDS, pg. 156, Abstract J 406
			Fultz et al, "HIV-Chimpanzee and SIVsmmPBj14-Macaque Mucosal Challenge Models for Testing Vaccine Efficacy", Prevention and Treatment of AIDS, pg. 156, Abstract J 407
			Cohen, "AIDS Vaccine - Are Researchers Racing Toward Success, or Crawling?", Science 265:1373-1375 (1994)
			Brown and Weiser, "HIV Infections Cast Pall Over Expanding Vaccine Experiments", The Washington Post, pg. A7, Monday, May 30, 1994

*Examiner		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1579-601	09/956,940
APPLICANT	
HAYNES, Barton F.	
FILING DATE	GROUP
September 21, 2001	1644

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

*EXAMINER INITIAL		
		Haynes et al, "Use of Synthetic Peptides in Primates to Induce High-Titered Neutralizing Antibodies and M Class I-Restricted Cytotoxic T Cells Against Acquired Immunodeficiency Syndrome Retroviruses: An HLA Based Vaccine Strategy", Transactions of the Association of American Physicians 106:31-41 (1993)
		Kast et al, "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Typ E6 and E7 Proteins", Journal of Immunology 152:3904-3912 (1994)
		Kubo et al, "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles", Journal of Immunology 152:3913-3924 (1994)
		de Lorimier et al, "NMR-Derived Solution Conformations of a Hybrid Synthetic Peptide Containing Multipl Epitopes of Envelope Protein gp120 from the RF Strain of Human Immunodeficiency Virus", Biochemistry 33(8):2055-2062 (1994)
		Golding et al, "Common Epitope in Human Immunodeficiency Virus (HIV) I-GP41 and HLA Class II Elicits Immunosuppressive Autoantibodies Capable of Contributing to Immune Dysfunction in HIV I-Infected Individuals", The Journal of Clinical Investigations, Inc. 83:1430-1435 (1989)
		Cotsamire et al, "Synthesis of HIV gp41 Fusion Seuqence N-terminal to the Hybrid T1-SP10 Peptide Yiel Peptides that Form High Molecular Weight Complexes in Aqueous solutions", Journal of Cellular Biochem Suppl 0 (16 Part E), pg. 10 (1992) – Abstract Q 406
		Haynes et al, "HIV Synthetic Peptides Containing T and B Cell Epitopes as Vaccine Candidates", Journal Cellular Biochemistry Suppl 0 (16 Part E), pg. 10 (1992) – Abstract Q 027
*Examiner		Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. In copy of this form with next communication to application.

Form PTO-FB-A820 (Also PT

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No.	Serial No.
1579-601	09/956,940
Applicant	
HAYNES, Barton F.	
Filing Date	**Group**
Septemb r 21, 2001	1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,030,449	7/1991	Berzofsky et al			
		5,853,978	12/1998	Berman et al			
		5,864,027	1/1999	Berman			
		5,932,218	8/1999	Berzofsky et al			
		5,939,074	8/1999	Berzofsky et al			
		6,042,836	3/2000	Berman et al			
		6,290,963	9/2001	Fischinger et al			
		6,294,322	9/2001	Berzofsky et al			
		6,458,527	10/2002	Luciw et al			
		5,081,226	1/1992	Berzofsky et al			
		5,336,758	8/1994	Berzofsky et al			
		5,622,703	4/1997	Berzofsky et al			
		5,695,762	12/1997	Berzofsky et al			
		5,711,947	1/1998	Berzofsky et al			
		5,820,865	10/1998	Berzofsky et al			
		5,882,853	3/1999	Berzofsky et al			
		5,976,541	11/1999	Berzofsky et al			
		5,980,899	11/1999	Berzofsky et al			
		5,997,869	12/1999	Goletz et al			
		6,214,347	4/2001	Berzofsky et al			
		6,592,872	7/2003	Klimpel et al			
		5,516,632	5/1996	Palker et al			
		5,352,576	10/1994	Haynes et al			
		5,993,819	11/1999	Haynes et al			
		5,019,387	5/1991	Haynes et al			
		5,013,548	5/1991	Haynes et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
		WO 93/04697 ✓	3/1993	WIPO				
		WO 94/26785 ✓	11/1994	WIPO				
		WO 94/28929 ✓	12/1994	WIPO				
		WO 94/29339 ✓	12/1994	WIPO				
		WO 98/01564 ✓	1/1998	WIPO				
		WO 01/56355 ✓	8/2001	WIPO				
		WO 95/29700 ✓	11/1995	WIPO				
		WO 93/15750 ✓	8/1993	WIPO				

*Examiner		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Atty. D cket No.	Serial No.
1579-601	09/956,940
Applicant	
HAYNES, Barton F.	
Filing Dat	**Group**
S ptemb r 21, 2001	1644

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

		Ahlers, et al., "Construction of an HIV-1 Peptide Vaccine Containing a Multideterminant Helper Peptide Linked to a V3 Loop Peptide 18 Inducing Strong Neutralizing Antibody Responses in Mice of Multiple MHC Haplotypes After Two Immunizations", The Journal of Immunology, Vol. 150, No. 12, pp. 5647-5665 (1993)
		Ahlers, et al., "Candidate HIV Type 1 Multideteminant Cluster Peptide-P18MN Vaccine Constructs Elicit Type 1 Helper T Cells, Cytotoxic T Cells, and Neutralizing Antibody, All Using the Same Adjuvant Immunization", AIDS Research and Human Retroviruses, Vol. 12, Number 4, pp. 259-272 (1996)
		Berzofsky, et al., "Antigenic Peptides Recognized by T lymphocytes from AIDS Viral Envelope-Immune Humans", Nature, Vol. 334, pp. 706-708 (1988)
		Clerici, et al., "Detection of Cytotoxic T Lymphocytes Specific for Synthetic Peptides of gp160 in HIV-Seropositive Individuals", The Journal of Immunology, Vol. 146, No. 7, pp. 2214-2219 (1991)
		Haynes, et al., "Conversion of an Immunogenic Human Immunodeficiency Virus (HIV) Envelope Synthetic Peptide to a Tolerogen in Chimpanzees by the Fusogenic Domain of HIV gp41 Envelope Protein", The Journal of Experimental Medicine, Vol. 177, pp. 717-727 (1993)
		Hosmalin, et al., "Priming with T Helper Cell Epitope Peptides Enhances the Antibody Response to the Envelope Glycoprotein of HIV-1 in Primates", The Journal of Immunology, Vol. 146, No. 5, pp. 1667-1673 (1991)
		Shirai, et al., "Broad Recognition of Cytotoxic T Cell Epitopes from the HIV-1 Envelope Protein with Multiple Class I Histocompatibility Molecules", The Journal of Immunology, Vol. 148, No. 6, pp. 1657-1667 (1992)
		Haynes et al, "Induction of HIVMN Neutralizing Antibodies in Primates Using a Prime-Boost Regimen of Hybrid Synthetic gp120 Envelope Peptides", The Journal of Immunology 151(3):1646-1653 (1993)
		Yasutomi et al, "Synthetic Peptide in Mineral Oil Adjuvant Elicits Simian Immunodeficiency Virus-Specific CD8+ Cytotoxic T Lymphocytes in Rhesus Monkeys", The Journal of Immunology 151(9):1-10 (1993)
		Cohen, "Jitters Jeopardize AIDS Vaccine Trials", Science 262:980-981 (1993)
		Norley and Kurth, "Vaccination against HIV", Immunobiol 184:193-207 (1992)
		Rowland-Jones et al, "HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women", Nat. Med. 1(1):59-64 (1995) – Abstract
		Plotkin and Mortimer, "New Technologies for Making Vaccines", W.B. Saunders Company, Vaccines 29:568-575 (1988)
		Takahashi et al, "An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes", Proc. Natl. Acad. Sci. USA 85:3105-3109 (1988)
		Haynes et al, "Human T Cell Antigen Expression by Primate T Cells", Science 215:298-300 (1982)

*Examiner		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 9 of 9

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1579-601	09/956,940
APPLICANT	
HAYNES, Barton F.	
FILING DATE	**GROUP**
September 21, 2001	1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	ENGLISH ABSTRACT YES	NO
	✓	WO 97/14436	4/1997	WIPO				
	✓	WO 02/08716	1/2002	WIPO			X	
	✓	WO 02/20554	3/2002	WIPO				
	✓	WO 02/24149	3/2002	WIPO				
	✓	WO 87/07616	12/1987	WIPO				
	✓	0 327 180	8/1989	EPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

		Liao et al, "Increased immunogenicity of HIV envelope subunit complexed with α_2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF", Vaccine 20:2396-2403 (2002)
		U.S. Patent Application No. 09/956,940
		U.S. Patent Application No. 10/289,228
		U.S. Patent Application No. 10/305,357

*Examiner | Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)